GLP-1R is a potent target for the treatment of type 2 diabetes mellitus (Redij et al., 2019), and small molecule agonists targeting GLP-1R can provide several potential benefits and overcome defects associated with peptide drugs. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.